NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ICU and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 22, 2025, ICU ...

ICU Medical (ICUI) came out with quarterly earnings of $1.72 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 39.84%. A quarter ago, it was expected that this medical device maker would post earnings of $1.48 per share when it actually produced earnings of $2.11, delivering a surprise of 42.57%.Over the last four quarters, the ...

ICU Medical (ICUI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants John Mills - Managing PartnerVivek Jain - Chairman & Chief Executive OfficerBrian Bonnell - Chief Financial OfficerJayson Bedford - Managing Director - Medical TechnologyJoseph Conway - Equity Research Associate Conference Call Participants Brett Fishbin - Vice President & Equity Research AnalystLarry Solow - Partner & Managing director - Equity AnalystMichael Toomey - US Medtech Analyst Operator Good day, and welcome to ...

ICU Medical (ICUI) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and welcome to the ICU Medical Inc. First Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be opportunity to ask questions. Please note today's event is being recorded. I'd like to now turn the conference over to John Mills. Please go ahead. Speaker1 Thank you. Good afternoon, everyone. Thank you for joining us to discuss ICU Medical' ...

ICU Medical, Inc Q1 2025 Conference Call Presentation May 8, 2025 1 Disclosures 2 > Any statement concerning Management's expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results. > Future results are subject to risks and uncertainties, including the risk factors described in the Company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File No.: 001-34634 ICU MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 33-0022692 Securities registered pursuant to Sectio ...

Exhibit 99.1 ICU Medical Announces First Quarter 2025 Results SAN CLEMENTE, Calif., May 8, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 ...

SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in ...

NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ICU Medical, Inc. (“ICU” or the “Company”) (NASDAQ: ICUI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether ICU and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 22, 2025, ICU d ...

The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market.SAN CLEMENTE, Calif. and TOKUSHIMA, Japan, May 1, 2025 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), a su ...